Diabetes Obesity and Metabolism · 2015 · 28 citations · 24 references
MedicineEndocrinologyPharmacotherapyDiabetologyGeriatric PharmacologyPharmacovigilanceDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyInsulin TherapyMedication Use EvaluationCohort Study InvestigationCox RegressionDiabetes Medication UseElectronic Medical RecordsKaplan-meier Confidence IntervalsLogistic RegressionPropensity Score AdjustmentStratified Kaplan-meier Estimation
AIM: To assess time to insulin initiation among patients with type 2 diabetes mellitus (T2DM) treated with sitagliptin versus sulphonylurea as add-on to metformin. METHODS: This retrospective cohort study used GE Centricity electronic medical records and included patients aged ≥18 years with continuous medical records and an initial prescription of sitagliptin or sulphonylurea (index date) with metformin for ≥90 days during 2006-2013. Sitagliptin and sulphonylurea users were matched 1 : 1 using propensity score matching, and differences in insulin initiation were assessed using Kaplan-Meier curves and Cox regression. We used conditional logistic regression to examine the likelihood of insulin use 1-6 years after the index date for each year. RESULTS: Propensity score matching produced 3864 matched pairs. Kaplan-Meier analysis showed that sitagliptin users had a lower risk of insulin initiation compared with sulphonylurea users (p = 0.003), with 26.6% of sitagliptin users initiating insulin versus 34.1% of sulphonylurea users over 6 years. This finding remained significant after adjusting for baseline characteristics (hazard ratio 0.76, 95% confidence interval 0.65-0.90). Conditional logistic regression analyses confirmed that sitagliptin users were less likely to initiate insulin compared with sulphonylurea users [odds ratios for years 1-6: 0.77, 0.79, 0.81, 0.57, 0.29 and 0.75, respectively (p < 0.05 for years 4 and 5)]. CONCLUSIONS: In this real-world matched cohort study, patients with T2DM treated with sitagliptin had a significantly lower risk of insulin initiation compared with patients treated with sulphonylurea, both as add-on to metformin.
24
Economic Costs of Diabetes in the U.S. in 2002
Paul Hogan, Plamen Nikolov · Diabetes Care · 2003 · 4.2K citations
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Steven E. Kahn, Steven M. Haffner, Mark Heise et al. · New England Journal of Medicine · 2006 · 2.9K citations